LAUSR

The studies on molecular interactions of drug candidates with HSA have considerably contributed to the understanding of primary biological evaluation of potential drug. In this context, Schiff base, ( E )-2-((2-hydroxy-3-methoxybenzylidene)amino)-6 H -benzo[ c ]chromen-6-one ( 1 ) derived from o-vanillin and 6-amino-3,4-benzocoumarin was synthesized and characterized by elemental analysis, UV–Vis, IR, NMR, and ESI–MS. The HSA interaction studies of compound 1 was carried out employing various biophysical techniques, viz ., UV–Vis titration, fluorescence quenching experiments, and CD measurements. The compound 1 displayed non-covalent hydrophobic mode of binding ( K b  = 3.4 × 10 3  M −1 ). The fluorescence spectroscopic results revealed that compound 1 exhibited strong capability to quench the intrinsic fluorescence of HSA at Trp 214 site ( K sv  = 4.1 × 10 3  M −1 ). Also ADME and Lipinski’s drug-likeness predicted favorable physicochemical properties for oral bioavailability. To ascertain the specific binding to HSA, molecular docking was performed deciphering that electrostatic steady-state interactions have key role in binding of compound 1 to HSA with ΔG of −9.21 kcal mol −1 . Moreover, DFT calculations were conducted to obtain electronic and structural properties of compound 1 . The theoretical calculations and the experimental data are in well agreement, and hence, the findings suggest that compound 1 might exhibit a potent role in the biomedical and pharmaceutical application.